Abstract: Objective To observe the clinical effect of xiaoer Xiaoji cough oral liquid combined with Montelukast sodium and Terbutaline in the treatment of chronic cough variant asthma CVA in children. Methods From January 2018 to December 2022, sixty patients with CVA were selected and randomly divided into treatment group and control group, with 30 Datients in each group. The control group was given atomized terbutaline, oral Montelukast sodium chewable tablets. On the basis of control group, xiaoer Xiaoji cough oral liquid was added to the treatment group, 3 times/day, 15~20 mL/time, for 14 consecutive days. The percentage of eosinophil granulosis (EOS), the level of hypersensitive C-reactive protein (hs-CRP), the duration of cough remission, clinical efficacy, and the incidence of adverse events were recorded and statistically analyzed before and after treatment. Results After treatment, EOS and hs-CRP in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the remission time of cough in treatment group was shorter than that in control group, and the difference was statistically significant (P<0.05). The effective rate of treatment group was higher than control group, and the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse events between the two groups (P>0.05). Conclusion Pediatric xiaoer Xiaoji cough oral liquid combined with Montelukast sodium and Terbutaline in the treatment of children's CVA can more effectively reduce blood inflammation indicators, improve cough symptoms faster, the incidence of adverse events during the treatment process did not increase, which is worthy of further clinical recommendation.

Key words: Xiaoer Xiaoji cough oral liquid, montelukast sodium, terbutaline, cough variant asthma in children